ESSA Pharma announced that it has entered into an Open Market Sale Agreement with Jefferies LLC, effective as of November 3, 2023. Under the ATM Sales Agreement, ESSA may sell its common shares in the capital of the Company from time to time for up to $50M in aggregate sales proceeds. No offers or sales of common shares will be made in Canada, to anyone known by Jefferies, LLC to be a resident of Canada or on or through the facilities of any stock exchange or trading markets in Canada.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EPIX:
- Essa Pharma presents Phase 1 clinical data of masofaniten in prostate cancer
- Essa Pharma presents updated Phase 1 Masofaniten clinical data
- Biotech Alert: Searches spiking for these stocks today
- Essa Pharma files $200M mixed securities shelf
- Essa Pharma initiates Phase 2 study of masofaniten/enzalutamide combo
